Insider Buying: ChromaDex Co. (NASDAQ:CDXC) CFO Purchases 2,907 Shares of Stock

ChromaDex Co. (NASDAQ:CDXC) CFO Ozan Pamir acquired 2,907 shares of the company’s stock in a transaction on Friday, November 22nd. The stock was bought at an average cost of $7.36 per share, with a total value of $21,395.52. Following the completion of the acquisition, the chief financial officer now directly owns 2,907 shares in the company, valued at approximately $21,395.52. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

ChromaDex Stock Up 0.3 %

ChromaDex stock opened at $7.46 on Tuesday. The stock has a market cap of $569.79 million, a PE ratio of 747.75 and a beta of 1.88. ChromaDex Co. has a 12-month low of $1.32 and a 12-month high of $7.85. The business’s 50-day moving average price is $4.61 and its two-hundred day moving average price is $3.59.

ChromaDex (NASDAQ:CDXC) last posted its quarterly earnings results on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. The company had revenue of $25.58 million for the quarter, compared to the consensus estimate of $23.70 million. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. During the same period last year, the company posted ($0.01) EPS. As a group, analysts expect that ChromaDex Co. will post 0.04 earnings per share for the current year.

Wall Street Analyst Weigh In

CDXC has been the subject of a number of analyst reports. HC Wainwright boosted their price target on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, November 4th. Roth Mkm upped their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Finally, StockNews.com cut shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 18th.

Institutional Trading of ChromaDex

Hedge funds and other institutional investors have recently modified their holdings of the stock. Barclays PLC boosted its holdings in shares of ChromaDex by 322.1% during the 3rd quarter. Barclays PLC now owns 70,072 shares of the company’s stock valued at $256,000 after acquiring an additional 53,472 shares in the last quarter. Geode Capital Management LLC raised its position in ChromaDex by 1.6% in the third quarter. Geode Capital Management LLC now owns 1,149,592 shares of the company’s stock valued at $4,197,000 after purchasing an additional 17,963 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of ChromaDex by 100.3% during the third quarter. Jane Street Group LLC now owns 45,712 shares of the company’s stock valued at $167,000 after purchasing an additional 22,889 shares in the last quarter. State Street Corp grew its holdings in shares of ChromaDex by 11.3% during the third quarter. State Street Corp now owns 618,028 shares of the company’s stock worth $2,256,000 after purchasing an additional 62,692 shares during the last quarter. Finally, MetLife Investment Management LLC increased its stake in shares of ChromaDex by 39.3% in the third quarter. MetLife Investment Management LLC now owns 18,114 shares of the company’s stock valued at $66,000 after buying an additional 5,115 shares during the period. Institutional investors own 15.41% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.